X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.fiercepharma.com/pharma/after-pfizer-offers-discount-nice-gives-thumbs-breast-cancer-drug-talzenna
https://www.fiercepharma.com/pharma/pfizers-talzenna-snags-broader-prostate-cancer-nod-astrazenecas-parp-remains-hopeful-further
https://www.onclive.com/view/fda-approves-talazoparib-plus-enzalutamide-for-hrr-gene-altered-mcrpc
https://www.fiercepharma.com/pharma/pfizer-touts-xtandi-backbone-talzenna-parp-prostate-cancer-battle-astrazeneca-jj
https://www.prnewswire.com/news-releases/senhwa-announces-first-patient-successfully-dosed-in-phase-i-study-of-pindnarulex-in-combination-with-pfizers-talazoparib-for-the-treatment-of-prostate-cancer-301663181.html
https://www.biospace.com/article/pfizer-s-talzenna-shows-early-promise-in-mcrpc/
https://www.globenewswire.com/news-release/2022/08/10/2495490/0/en/Artios-initiates-Phase-2-study-of-Pol%CE%B8-Inhibitor-ART4215-in-Combination-with-PARP-Inhibitor-Talazoparib-in-BRCA-Deficient-Breast-Cancer.html
https://www.prnewswire.com/news-releases/senhwas-pindnarulex-in-combination-study-with-pfizers-talazoparib-for-the-treatment-of-prostate-cancer-granted-approval-to-initiate-from-australian-hrec-301561734.html
https://www.clinicaltrialsarena.com/news/zenith-breast-cancer-trial/
https://breastcancernow.org/about-us/media/press-releases/existing-drug-could-offer-new-hope-people-secondary-breast-cancer-has-spread-brain
http://www.pharmatimes.com/news/new_brca-targeting_drug_could_treat_advanced_prostate_cancer_1375585
https://www.iqwig.de/en/press/press-releases/talazoparib-in-breast-cancer-hint-of-considerable-added-benefit.13263.html
https://www.onclive.com/conference-coverage/aacr-2020/talazoparib-improves-qol-but-not-os-in-advanced-brca12-breast-cancer
https://www.fiercepharma.com/pharma/gsk-wins-fda-priority-review-for-zejula-late-stage-ovarian-cancer
https://www.prnewswire.com/news-releases/biomarin-earns-milestone-payments-from-pfizer-for-talzenna-talazoparib-for-metastatic-breast-cancer-patients-with-an-inherited-brca-mutation-300872717.html
http://www.pharmatimes.com/news/pfizer_talzenna_leads_latest_chmp_highlights_1285996
https://press.pfizer.com/press-release/pfizer-receives-positive-chmp-opinion-talzenna-talazoparib-patients-inherited-germline
https://xconomy.com/boston/2018/12/03/gsk-pays-5-1b-for-tesaro-setting-up-parp-battle-with-rival-astrazeneca/
https://globenewswire.com/news-release/2018/10/10/1619098/0/en/Myriad-Announces-New-Laboratory-Agreement-with-Pfizer.html
https://www.fiercepharma.com/pharma/pfizer-finally-breaks-into-parp-market-breast-cancer-as-rivals-pull-ahead-new-indications
https://endpts.com/pfizer-bags-an-fda-ok-for-parp-player-talazoparib-now-the-hard-part-begins/
https://www.prnewswire.com/news-releases/biomarin-receives-milestone-payments-from-pfizer-for-talzenna-talazoparib-for-metastatic-breast-cancer-patients-with-an-inherited-brca-mutation-300732054.html
https://www.forbes.com/sites/greatspeculations/2018/07/02/how-sensitive-is-pfizer-to-rd-expense-changes/#1a6f7f16230f
https://globenewswire.com/news-release/2018/06/18/1525702/0/en/Myriad-s-BRACAnalysis-CDx-Supplementary-PMA-Accepted-by-FDA-for-Review-as-a-Companion-Diagnostic-for-Talazoparib-in-Metastatic-Breast-Cancer.html
http://www.pharmatimes.com/news/pfizer_files_parp_inhibitor_for_breast_cancer_in_us,_eu_1239074
https://www.fiercepharma.com/pharma/pfizer-wins-appeal-ps84m-fine-over-u-k-epilepsy-drug-price-hike
https://endpts.com/mega-blockbuster-pfizer-lines-up-for-a-snap-review-of-its-parp-drug-talazoparib-and-a-launch-into-a-crowded-market/
https://www.fiercepharma.com/pharma/parp-battle-heats-up-as-pfizer-nabs-priority-review-for-talazoparib-breast-cancer
https://www.prnewswire.com/news-releases/biomarin-receives-milestone-payments-from-pfizer-for-talazoparib-300661265.html
https://www.forbes.com/sites/victoriaforster/2018/05/10/scientists-identify-why-some-people-may-be-resistant-to-parp-inhibitor-drugs/?ss=pharma-healthcare#4ea11437150a
https://endpts.com/in-a-showdown-with-astrazeneca-pfizer-posts-solid-and-very-familiar-phiii-breast-cancer-data-for-talazoparib/
Market Place
Share 
